Table 1.
Demographic and clinical information of sarcoidosis patients and healthy controls.
| CASES | CONTROLS | |
|---|---|---|
| Demographic features | ||
| Gender n(%) | ||
| Male | 12 (34.3) | 3 (23.1) |
| Female | 23 (65.7) | 10 (76.9) |
| Race n(%) | ||
| European American | 27 (77.1) | 12 (92.3) |
| African American | 6 (17.1) | 1 (7.7) |
| Native American | 2 (5.7) | 0 (0) |
| Mean age in years (SD) | 57 (10.8) | 45 (12) |
| Disease Activity n(%) | ||
| Active* | 12 (34.3) | n/a |
| Not-active | 23 (65.7) | n/a |
| Disease Duration n(%) | ||
| Chronic† (>2 years) | 15 (42.8) | n/a |
| Persistent (>5 years) | 11 (31.4) | n/a |
| Organ Involvement n(%)§,‡ | ||
| Lungs | 35 (100) | n/a |
| Extra-thoracic lymph nodes | 14 (40) | n/a |
| Calcium/Vitamin D | 7 (20) | n/a |
| Liver | 4 (11.4) | n/a |
| Spleen | 4 (11.4) | n/a |
| Eyes | 4 (11.4) | n/a |
| Skin | 3 (8.6) | n/a |
| Bone/Joints | 3 (8.6) | n/a |
| Bone marrow | 2 (5.7) | n/a |
| Kidney | 2 (5.7) | n/a |
| ENT | 1 (2.9) | n/a |
| Nervous system | 1 (2.9) | n/a |
| Heart | 1 (2.9) | n/a |
| Other | 1 (2.9) | n/a |
| Medication usage at collection n(%)§,ll | ||
| Prednisone | 13 (37.1) | 1 (7.7) |
| Methotrexate | 4 (11.4) | n/a |
| Hydroxychloroquine | 3 (8.6) | n/a |
| Azathioprine | 2 (5.7) | n/a |
| Infliximab | 2 (5.7) | n/a |
| Adalimumab | 1 (2.9) | n/a |
| Golimumab | 1 (2.9) | n/a |
*Defined as having exhibited (per medical records) novel organ involvement or a decrease in forced vital capacity of >10% in the last 12 months. †Defined as unresolved disease lasting longer than 2 years. ‡According to recommendations (18, 19). §A subject may have multiple organs affected or take multiple medications. ll Medications may have been taken for any cause, not exclusively for treatment of sarcoidosis.